Oramed Pharmaceuticals Income Statement (2022-2025) | ORMP

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) 0.67M0.67M0.68M0.90M0.67M0.67M-0.59M-0.26M2.00M
Cost of Revenue (Quarter) 0.59M0.38M0.46M0.18M0.19M0.66M1.99M
Gross Profit (Quarter) 0.08M0.29M0.22M0.48M0.48M-0.66M0.01M
Operating items
Research & Development (Quarter) 5.84M9.18M5.35M9.04M4.43M1.82M0.96M1.77M1.18M1.44M2.24M2.21M1.03M1.15M1.52M
Selling, General & Administrative (Quarter) 5.49M2.53M3.06M2.73M1.26M2.45M2.60M2.11M1.78M1.69M0.85M2.31M1.46M1.27M4.40M
Operating Expenses (Quarter) 11.33M11.71M8.41M11.76M5.69M4.27M3.56M3.88M2.96M3.13M3.09M4.51M2.49M2.43M5.92M
Operating Income (Quarter) -11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M12.96M-2.96M-3.13M-3.09M-4.50M-2.49M-2.43M25.00M
EBIT (Quarter) -11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M12.96M-2.96M-3.13M-3.09M-4.50M-2.49M-2.43M25.00M
Non-operating items
Other Non Operating Income (Quarter) 3.55M16.65M-3.62M16.54M32.28M-0.71M
Non Operating Income (Quarter) 1.04M1.00M1.60M2.48M0.43M-4.50M3.55M14.23M-15.42M-3.62M15.37M61.47M85.55M
Net income details
EBT (Quarter) -11.25M-11.42M-7.15M-12.26M-5.21M-1.31M-3.28M13.30M1.53M10.84M-18.51M-7.06M13.13M59.45M81.46M
Tax Provisions (Quarter) 0.10M1.63M1.13M0.58M-0.13M11.06M8.54M
Profit After Tax (Quarter) -10.71M-10.53M-7.06M-12.26M-3.61M-1.19M-3.22M13.30M1.54M9.20M-19.62M-7.64M7.52M48.39M29.31M
Income from Non-Controlling Interests (Quarter) -0.28M-0.53M-0.19M-0.59M-0.22M-0.12M-0.06M0.83M-0.00M-0.01M-0.02M-0.03M-0.01M-0.00M
Income from Continuing Operations (Quarter) -11.25M-11.42M-7.25M-12.26M-5.21M-1.31M-3.28M13.30M1.53M9.20M-19.64M-7.64M13.26M48.39M72.92M
Consolidated Net Income (Quarter) -11.25M-11.42M-7.25M-12.26M-5.21M-1.31M-3.28M13.30M1.53M9.20M-19.64M-7.64M13.26M48.39M72.92M
Income towards Parent Company (Quarter) -11.25M-11.42M-7.25M-12.26M-5.21M-1.31M-3.28M13.30M1.53M9.20M-19.64M-7.64M13.26M48.39M72.92M
Net Income towards Common Stockholders (Quarter) -10.43M-10.53M-7.06M-11.67M-3.40M-1.31M-3.28M13.30M1.53M9.20M-19.64M-7.64M13.26M48.39M72.92M
Additional items
EPS (Basic) (Quarter) 0.270.270.180.31-0.08-0.03-0.080.330.040.22-0.48-0.190.321.161.75
EPS (Weighted Average and Diluted) (Quarter) -0.27-0.27-0.18-0.30-0.08-0.03-0.080.330.040.22-0.48-0.190.311.131.72
Shares Outstanding (Weighted Average) (Quarter) 38.68M38.73M39.10M39.00M40.04M40.23M40.25M40.32M40.84M40.90M40.88M41.23M41.74M41.76M41.40M
Shares Outstanding (Diluted Average) (Quarter) 38.68M38.73M38.86M39.00M40.04M40.23M40.45M40.57M41.56M41.43M40.90M41.23M42.88M42.97M42.42M
EBITDA (Quarter) -11.25M-11.42M-8.19M-12.33M-5.21M-3.79M-2.89M12.96M-2.96M-3.13M-3.09M-4.50M-2.49M-2.43M25.00M
Interest Expenses (Quarter) 0.83M1.21M0.59M0.26M
Tax Rate (Quarter) -1.40%15.08%-6.12%-8.27%-0.96%18.61%10.48%